title: Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?
abstract: OBJECTIVE
  Our aim was to examine the clinicopathologic characteristics and survival of ovarian, tubal, and peritoneal (further denoted "adnexal") cancer in BRCA1 compared with BRCA2 carriers.
  
  
  METHODS
  A consecutive series of adnexal cancers in BRCA1/2 mutation carriers diagnosed in 1980 to 2010 at the University Medical Center Groningen was analyzed.
  
  
  RESULTS
  We evaluated 55 BRCA1- and 16 BRCA2-related adnexal cancers, consisting of 51 ovarian, 13 tubal, and 7 peritoneal cancers. Peritoneal cancer was restricted to BRCA1 carriers. Ovarian and tubal cancer was equally present in both carrier groups. Median age at diagnosis was younger in BRCA1 compared with BRCA2 carriers (50 vs 54 years; P = 0.03). No other clinicopathologic differences were found. Regarding survival, a nonsignificant trend was noted for BRCA2 carriers to have fewer relapses, a longer time to first relapse, and a longer disease-free and overall survival.
  
  
  CONCLUSIONS
  Except for age at diagnosis and prevalence of peritoneal cancer, no significant clinicopathologic differences were found between BRCA1- versus BRCA2-associated adnexal cancer. On survival, it might be suggested that BRCA2 carriers have a more favorable outcome than BRCA1 carriers, marked by fewer relapses, a longer time to first relapse, and a longer disease-free and overall survival.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University Medical Center Groningen, Groningen, the Netherlands.
authors.forename: Welmoed
authors.initials: W
authors.lastname: Reitsma
authors.forename: Geertruida H
authors.initials: GH
authors.lastname: de Bock
authors.forename: Jan C
authors.initials: JC
authors.lastname: Oosterwijk
authors.forename: Klaske A
authors.initials: KA
authors.lastname: ten Hoor
authors.forename: Harry
authors.initials: H
authors.lastname: Hollema
authors.forename: Marian J E
authors.initials: MJ
authors.lastname: Mourits
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000235:genetics / Q000401:mortality / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000235:genetics / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D015331:Cohort Studies; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000401:mortality / Q000473:pathology; D016889:Endometrial Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology; D005185:Fallopian Tube Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology*; D010534:Peritoneal Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human